Cognis develops active ingredients from IMD

Cognis has now exclusively licensed two new active ingredients for weight management and cognitive performance from InterMed Discovery (IMD).

Tests on the products Cognis has acquired from IMD are already delivering promising results.

The sales potential is increasing for active ingredients in functional foods to support weight management and benefit heart and brain health, largely because obesity is becoming a major public health problem in many parts of the world and the society is generally getting older.

During their ongoing collaboration, both companies used IMD's database of biologically active natural substances and IMD Bioprofiling technology platform to discover innovative functional ingredients for specific food applications, and to bring suitable active substances to market-readiness.

As a result of Cognis' research, it obtained insights into aspects of brain health such as learning ability, cognitive performance (and ways of maintaining this with age), alertness, and concentration.

One of the candidates is a new ingredient that is showing promising benefits for weight management in different test systems.

The second new ingredient is a promising product for improving brain health, as in vivo tests have shown potential on cognitive performance.

Cognis plans to carry out further in vivo tests and research studies for these ingredients later this year.

Cognis has previously licensed four other ingredients from IMD targeting weight management and heart health.

Clinical studies for one of these projects will begin later this year.

The other licensed ingredients are currently in advanced preclinical testing and scale-up process.